American College of Emergency Physicians Warns Against COVID-19 Misinformation

American College of Emergency Physicians (ACEP) cautions everyone to be wary of unsourced information or opinion masquerading as public health advice during the ongoing COVID-19 crisis.

ACEP urges the public to be circumspect of bold claims or instant cures made on social media or circulating among friends. Instead, seek information supported by data and endorsed by leading health and medical expert entities like ACEP, the Centers for Disease Control and Prevention (CDC) or others.

“A troubling number of purported experts are sharing false and dangerous information that runs counter to the public health and safety guidelines endorsed by ACEP and the nation’s leading medical and public health entities,” said William Jaquis, MD, FACEP, president of ACEP. “This kind of misinformation can not only be harmful to individuals, but it hinders our nation’s efforts to get the pandemic under control.”

There is currently no cure or vaccine for COVID-19. Researchers and scientists are continuously learning more about the virus and how to treat it, and their expert guidance is updated accordingly. Anyone can spread COVID-19, even those who do not suspect they are infected. The CDC states that 40 percent of positive cases occur with people who show no symptoms (asymptomatic) but can still spread the virus. That does not mean the virus is “harmless.” The long-term effects of carrying the virus are still being studied.

Meanwhile, cases are surging in most states and tests are in short supply as demands on hospital beds and resources approach or exceed capacity. Whether your community is experiencing a surge or not, you can be assured that the emergency department is the best place to be if you think you are having a medical emergency. Emergency physicians are ready and able to care for you anytime and are specially trained to keep you safe even in the midst of a pandemic.

Information evolves and sound scientific reasoning can change as new information comes to light. As you consult with your health care provider or local health authorities, look for information backed by data and supported by consensus. Heeding unsubstantiated advice opens you to avoidable health risks.

Without a cure, smart personal choices and safe behaviors are the best defense against spreading COVID-19 and overwhelming our health care system.

“There are still many questions about COVID-19 but we know these three simple steps offer the best protection that we have until a vaccine is developed; cover your face, wash your hands frequently and practice social distancing,” said Dr. Jaquis.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version